Nanocarrier-mediated Delivery of CORM-2 Enhances Anti-allodynic and Anti-hyperalgesic Effects of CORM-2
- 150 Downloads
Neuropathic pain is a devastating chronic condition and effective treatments are still lacking. Carbon monoxide-releasing molecule-2 (CORM-2) as a carbon monoxide (CO) carrier, exerts potent anti-neuropathic pain effects; however, its poor water solubility and short half-life hinder its clinical utility. Therefore, the aim of this study was to investigate whether CORM-2-loaded solid lipid nanoparticles (CORM-2-SLNs) enhance the anti-allodynic and anti-hyperalgesic effects of CORM-2 in a rat chronic constriction injury (CCI) model. CORM-2-SLNs were prepared using a nanotemplate engineering technique with slight modifications. The physiochemical properties of CORM-2-SLNs were characterized and CO release from CORM-2-SLNs was assessed using a myoglobin assay. CO was slowly released from CORM-2-SLNs, was observed, and the half-life of CO release was 50 times longer than that of CORM-2. In vivo results demonstrate that intraperitoneal administration of CORM-2-SLNs (5 and 10 mg/kg/day, ip) once daily for seven consecutive days significantly reduced the mechanical allodynia and mechanical hyperalgesia compared with CORM-2 (10 mg/kg/day, ip). RT-PCR and Western blot analyses on days 7 and 14, revealed that treatment with CORM-2-SLNs resulted in greater reductions in the CCI-elevated levels of heme-oxygenase-2 (HO-2); inducible nitric oxide synthase (iNOS); neuronal NOS (nNOS); and inflammatory mediators (TNF-α, IBA-1, and GFAP) in the spinal cord and dorsal root ganglions compared with treatment with CORM-2. In contrast, HO-1 and IL-10 were significantly increased in the CORM-2-SLN-treated group compared with the group treated with CORM-2. These data indicate that CORM-2-SLNs are superior to CORM-2-S in alleviating mechanical allodynia and mechanical hyperalgesia.
KeywordsNeuropathic pain Nanoparticles Allodynia Hyperalgesia Carbon monoxide releasing molecule Carbon monoxide
This research was supported by the National Research Foundation (NRF) of Korea (NRF2017R1C1B1011397) and Korea Health Technology Research and Development Project, Ministry for Health and Welfare Affairs (HI16C1559, HI18C0183). This work was supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF-2017R1A2B4006458).
IBH and JKK conceived and directed the project. IBH, HPJ, and HK designed the whole experimental plan. HPJ, MJJ, HC, JK, SK, and KW carried out the experiments. SBK, SS, and KTK analyzed the data and interpreted the result. IBH, HPJ, SBK, and SK wrote the paper. All authors reviewed the manuscript.
Compliance with Ethical Standards
The authors declare that they have no competing interests.
- 2.Riego G, Redondo A, Leánez S, Pol O (2018) Mechanism implicated in the anti-allodynic and anti-hyperalgesic effects induced by the activation of heme oxygenase 1/carbon monoxide signaling pathway in the central nervous system of mice with neuropathic pain. Biochem Pharmacol 148:52–63PubMedCrossRefGoogle Scholar
- 12.Marques AR, Kromer L, Gallo DJ, Penacho N, Rodrigues SS, Seixas JD, Bernardes GJ, Reis PM et al (2012) Generation of carbon monoxide releasing molecules (CO-RMs) as drug candidates for the treatment of acute liver injury: targeting of CO-RMs to the liver. Organometallics 31(16):5810–5822CrossRefGoogle Scholar
- 13.Motterlini R (2007) Carbon monoxide-releasing molecules (CO-RMs): vasodilatory, anti-ischaemic and anti-inflammatory activities. Portland Press LimitedGoogle Scholar
- 18.Severino P, Andreani T, Macedo AS, Fangueiro JF, Santana MHA, Silva AM, Souto EB (2012) Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliver 1:10Google Scholar
- 24.Atkin AJ, Lynam JM, Moulton BE, Sawle P, Motterlini R, Boyle NM, Pryce MT, Fairlamb IJ (2011) Modification of the deoxy-myoglobin/carbonmonoxy-myoglobin UV-Vis assay for reliable determination of CO-release rates from organometallic carbonyl complexes. Dalton Trans 40(21):5755–5761PubMedCrossRefGoogle Scholar
- 35.Kim D-S, Figueroa KW, Li K-W, Boroujerdi A, Yolo T, Luo ZD (2009) Profiling of dynamically changed gene expression in dorsal root ganglia post peripheral nerve injury and a critical role of injury-induced glial fibrillary acetic protein in maintenance of pain behaviors. Pain 143(1–2):114–122PubMedPubMedCentralCrossRefGoogle Scholar
- 36.Olmos G, Lladó J (2014) Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediat InflammGoogle Scholar
- 41.Tanabe M, Nagatani Y, Saitoh K, Takasu K, Ono H (2009) Pharmacological assessments of nitric oxide synthase isoforms and downstream diversity of NO signaling in the maintenance of thermal and mechanical hypersensitivity after peripheral nerve injury in mice. Neuropharmacology 56(3):702–708PubMedCrossRefGoogle Scholar
- 42.Kim KM, Pae H-O, Zhung M, Ha H-Y, Ha YA, Chai K-Y, Cheong Y-K, Kim J-M et al (2008) Involvement of anti-inflammatory heme oxygenase-1 in the inhibitory effect of curcumin on the expression of pro-inflammatory inducible nitric oxide synthase in RAW264. 7 macrophages. Biomed Pharmacother 62(9):630–636PubMedCrossRefGoogle Scholar